LT3658148T - Makrocikliniai junginiai ir jų panaudojimas - Google Patents
Makrocikliniai junginiai ir jų panaudojimasInfo
- Publication number
- LT3658148T LT3658148T LTEPPCT/US2018/043817T LTUS2018043817T LT3658148T LT 3658148 T LT3658148 T LT 3658148T LT US2018043817 T LTUS2018043817 T LT US2018043817T LT 3658148 T LT3658148 T LT 3658148T
- Authority
- LT
- Lithuania
- Prior art keywords
- macrocyclic compounds
- macrocyclic
- compounds
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538193P | 2017-07-28 | 2017-07-28 | |
| US201862700990P | 2018-07-20 | 2018-07-20 | |
| PCT/US2018/043817 WO2019023417A1 (en) | 2017-07-28 | 2018-07-26 | MACROCYCLIC COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3658148T true LT3658148T (lt) | 2024-09-10 |
Family
ID=65039935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2018/043817T LT3658148T (lt) | 2017-07-28 | 2018-07-26 | Makrocikliniai junginiai ir jų panaudojimas |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US11286264B2 (OSRAM) |
| EP (1) | EP3658148B1 (OSRAM) |
| JP (2) | JP7224334B2 (OSRAM) |
| KR (1) | KR102645316B1 (OSRAM) |
| CN (1) | CN111182903A (OSRAM) |
| AU (1) | AU2018306328B2 (OSRAM) |
| BR (1) | BR112020001695A2 (OSRAM) |
| CA (1) | CA3069232A1 (OSRAM) |
| CL (1) | CL2020000169A1 (OSRAM) |
| CO (1) | CO2020000633A2 (OSRAM) |
| DK (1) | DK3658148T3 (OSRAM) |
| ES (1) | ES2986593T3 (OSRAM) |
| FI (1) | FI3658148T3 (OSRAM) |
| HR (1) | HRP20241197T1 (OSRAM) |
| IL (1) | IL271964B2 (OSRAM) |
| LT (1) | LT3658148T (OSRAM) |
| MY (1) | MY201925A (OSRAM) |
| PE (1) | PE20200700A1 (OSRAM) |
| PH (1) | PH12020500033A1 (OSRAM) |
| PL (1) | PL3658148T3 (OSRAM) |
| PT (1) | PT3658148T (OSRAM) |
| RS (1) | RS65884B1 (OSRAM) |
| SA (1) | SA520411108B1 (OSRAM) |
| SG (1) | SG11202000356VA (OSRAM) |
| SI (1) | SI3658148T1 (OSRAM) |
| SM (1) | SMT202400343T1 (OSRAM) |
| TW (1) | TWI818917B (OSRAM) |
| UA (1) | UA126158C2 (OSRAM) |
| WO (1) | WO2019023417A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3636649T (lt) | 2014-01-24 | 2024-04-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklai kaip proteinkinazių moduliatoriai |
| US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| ES2818528T3 (es) | 2015-07-21 | 2021-04-13 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer |
| EP3490564A4 (en) | 2016-07-28 | 2020-02-26 | Turning Point Therapeutics, Inc. | MACRO CYCLE Kinase Inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| EP3658148B1 (en) | 2017-07-28 | 2024-07-10 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
| CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
| MX2020006490A (es) | 2017-12-19 | 2020-08-17 | Turning Point Therapeutics Inc | Compuestos macrociclicos para tratar enfermedades. |
| PL3786167T3 (pl) | 2018-04-25 | 2024-11-25 | Primegene (Beijing) Co., Ltd. | Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanie |
| FI3870579T3 (fi) | 2018-10-22 | 2025-01-02 | Alumis Inc | Tyk2-inhibiittoreita ja niiden käyttöjä |
| CN113811534B (zh) * | 2019-03-11 | 2024-10-29 | 阿鲁米斯公司 | Tyk2抑制剂和其用途 |
| US12410191B2 (en) | 2019-05-21 | 2025-09-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Macrolide derivatives, preparation method and application thereof |
| CN114423762B (zh) * | 2019-09-30 | 2024-03-29 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
| EP4114530A4 (en) * | 2020-03-02 | 2024-04-17 | Turning Point Therapeutics, Inc. | Therapeutic uses of macrocyclic compounds |
| WO2021244609A1 (zh) * | 2020-06-04 | 2021-12-09 | 成都倍特药业股份有限公司 | 具有大环结构的化合物及其用途 |
| CN111620881B (zh) * | 2020-07-08 | 2023-03-31 | 浙江合聚生物医药有限公司 | 拉罗替尼衍生物及其制备方法和应用 |
| CN116635076A (zh) * | 2020-12-17 | 2023-08-22 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| CN114685532A (zh) * | 2020-12-31 | 2022-07-01 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| CN116829562B (zh) * | 2021-02-10 | 2025-04-01 | 深圳国顺康医药科技有限公司 | 一种巨环化合物、药物组合物以及其用途 |
| UY39779A (es) * | 2021-05-21 | 2023-01-31 | Blossomhill Therapeutics Inc | Compuestos macrocíclicos para tratar enfermedades |
| WO2023078267A1 (zh) * | 2021-11-02 | 2023-05-11 | 赛诺哈勃药业（成都）有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
| US12168640B2 (en) | 2021-11-16 | 2024-12-17 | ProDeg, LLC | USP9X inhibitors |
| CA3237744A1 (en) * | 2021-11-16 | 2023-05-25 | Richard Martinelli | Usp9x inhibitors |
| KR20240128987A (ko) | 2021-12-30 | 2024-08-27 | 바이오메아 퓨전, 인크. | Flt3의 억제제로서의 피라진 화합물 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE195935T1 (de) | 1993-03-25 | 2000-09-15 | Upjohn Co | Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung |
| NO308798B1 (no) | 1993-12-07 | 2000-10-30 | Lilly Co Eli | Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| WO2002016369A2 (en) | 2000-08-25 | 2002-02-28 | Sloan-Kettering Institute For Cancer Research | Novel macrocycles and uses thereof |
| AU2002227371B2 (en) | 2000-12-08 | 2007-05-10 | Ortho-Mcneil Pharmaceutical, Inc. | Macroheterocylic compounds useful as kinase inhibitors |
| CN102143750B (zh) | 2008-09-08 | 2014-04-02 | 默克专利有限公司 | 用作蛋白激酶抑制剂的大环嘧啶 |
| US8450322B2 (en) | 2008-09-22 | 2013-05-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors |
| TR201807039T4 (tr) | 2008-10-22 | 2018-06-21 | Array Biopharma Inc | Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri. |
| JP5769199B2 (ja) | 2008-10-31 | 2015-08-26 | ジェネンテック， インコーポレイテッド | ピラゾロピリミジンｊａｋ阻害剤化合物と方法 |
| AU2010305805B2 (en) | 2009-10-13 | 2014-04-03 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| ES2628418T3 (es) | 2010-05-20 | 2017-08-02 | Array Biopharma, Inc. | Compuestos macrocíclicos como inhibidores de la TRK cinasa |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| US9005394B2 (en) | 2011-06-10 | 2015-04-14 | Maintech Co., Ltd. | Anti-soiling agent composition |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| KR20140053330A (ko) | 2011-08-19 | 2014-05-07 | 머크 샤프 앤드 돔 코포레이션 | 마크로락탐의 제조를 위한 방법 및 중간체 |
| JP6046728B2 (ja) | 2011-09-30 | 2016-12-21 | オンコデザイン エス．ア． | 大環状ｆｌｔ３キナーゼ阻害剤 |
| PT2822953T (pt) | 2012-03-06 | 2017-04-06 | Pfizer | Derivados macrocíclicos para o tratamento de doenças proliferativas |
| CA2866164C (en) | 2012-03-09 | 2020-07-07 | Lexicon Pharmaceuticals, Inc. | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
| IN2014DN07384A (OSRAM) | 2012-03-09 | 2015-04-24 | Lexicon Pharmaceuticals Inc | |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| LT3636649T (lt) | 2014-01-24 | 2024-04-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklai kaip proteinkinazių moduliatoriai |
| TWI736134B (zh) * | 2014-09-11 | 2021-08-11 | 美商特普醫葯公司 | 作為蛋白質激酶之調節劑的二芳基巨環 |
| US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| SMT202400213T1 (it) | 2015-07-06 | 2024-07-09 | Turning Point Therapeutics Inc | Polimorfo di diaril macrociclo |
| ES2818528T3 (es) | 2015-07-21 | 2021-04-13 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer |
| AR106595A1 (es) * | 2015-11-06 | 2018-01-31 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
| EP3490564A4 (en) * | 2016-07-28 | 2020-02-26 | Turning Point Therapeutics, Inc. | MACRO CYCLE Kinase Inhibitors |
| JP7046940B2 (ja) * | 2016-10-28 | 2022-04-04 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| EP3658148B1 (en) * | 2017-07-28 | 2024-07-10 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
| WO2019120267A1 (zh) | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| EP3783000B1 (en) | 2018-04-18 | 2022-07-06 | Hitgen Inc. | Macrocyclic kinase inhibitor |
-
2018
- 2018-07-26 EP EP18838274.1A patent/EP3658148B1/en active Active
- 2018-07-26 SG SG11202000356VA patent/SG11202000356VA/en unknown
- 2018-07-26 JP JP2020504026A patent/JP7224334B2/ja active Active
- 2018-07-26 MY MYPI2019007871A patent/MY201925A/en unknown
- 2018-07-26 US US16/634,289 patent/US11286264B2/en active Active
- 2018-07-26 UA UAA202000271A patent/UA126158C2/uk unknown
- 2018-07-26 WO PCT/US2018/043817 patent/WO2019023417A1/en not_active Ceased
- 2018-07-26 PT PT188382741T patent/PT3658148T/pt unknown
- 2018-07-26 RS RS20240945A patent/RS65884B1/sr unknown
- 2018-07-26 BR BR112020001695-0A patent/BR112020001695A2/pt not_active Application Discontinuation
- 2018-07-26 HR HRP20241197TT patent/HRP20241197T1/hr unknown
- 2018-07-26 KR KR1020207000229A patent/KR102645316B1/ko active Active
- 2018-07-26 DK DK18838274.1T patent/DK3658148T3/da active
- 2018-07-26 AU AU2018306328A patent/AU2018306328B2/en active Active
- 2018-07-26 SM SM20240343T patent/SMT202400343T1/it unknown
- 2018-07-26 CA CA3069232A patent/CA3069232A1/en active Pending
- 2018-07-26 ES ES18838274T patent/ES2986593T3/es active Active
- 2018-07-26 FI FIEP18838274.1T patent/FI3658148T3/fi active
- 2018-07-26 LT LTEPPCT/US2018/043817T patent/LT3658148T/lt unknown
- 2018-07-26 PE PE2020000127A patent/PE20200700A1/es unknown
- 2018-07-26 CN CN201880049611.1A patent/CN111182903A/zh active Pending
- 2018-07-26 IL IL271964A patent/IL271964B2/en unknown
- 2018-07-26 PL PL18838274.1T patent/PL3658148T3/pl unknown
- 2018-07-26 SI SI201831143T patent/SI3658148T1/sl unknown
- 2018-07-27 TW TW107126181A patent/TWI818917B/zh active
-
2020
- 2020-01-02 PH PH12020500033A patent/PH12020500033A1/en unknown
- 2020-01-20 CL CL2020000169A patent/CL2020000169A1/es unknown
- 2020-01-21 CO CONC2020/0000633A patent/CO2020000633A2/es unknown
- 2020-01-21 SA SA520411108A patent/SA520411108B1/ar unknown
-
2021
- 2021-03-25 US US17/213,093 patent/US11155563B2/en active Active
-
2022
- 2022-02-22 US US17/676,942 patent/US11981684B2/en active Active
-
2023
- 2023-02-07 JP JP2023016586A patent/JP7554300B2/ja active Active
-
2024
- 2024-04-09 US US18/630,760 patent/US20240391935A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271964A (en) | Macrocyclic compounds and their uses | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| GB201714745D0 (en) | New compounds and uses | |
| IL292488B1 (en) | Pyridineamine-pyridone and pyrimidineamine-pyridone compounds | |
| IL288991A (en) | A macrocyclic compound and its uses | |
| GB201714734D0 (en) | New compounds and uses | |
| GB201714740D0 (en) | New compounds and uses | |
| IL292482B1 (en) | Azaindolylpyridone and diazaindolylpyridone compounds | |
| GB201714736D0 (en) | New compounds and uses | |
| GB201712110D0 (en) | New compounds and uses | |
| GB201700404D0 (en) | Compounds and composistions | |
| GB201810121D0 (en) | Macrocyclic compounds and uses thereof | |
| HK40032561A (en) | Macrocyclic compounds and uses thereof | |
| GB201720092D0 (en) | New Compounds and uses | |
| GB201719327D0 (en) | New compounds and uses | |
| GB201719233D0 (en) | New compounds and uses | |
| GB201715210D0 (en) | Macrocyclic compounds | |
| GB201714743D0 (en) | New compounds and uses | |
| GB201704121D0 (en) | Macrocyclic compounds | |
| GB201704125D0 (en) | Macrocyclic Compounds |